Retatrutide TRIUMPH-1 Phase 3 Results: How to Read the 28.3% Figure

The headline result, stated plainly

On May 21, 2026, Eli Lilly put out the first pivotal phase 3 readout for retatrutide, and the number everybody is repeating is real: up to 28.3% mean weight loss at 80 weeks. TRIUMPH-1 randomized 2,339 adults with obesity or overweight, none of them diabetic, into four groups: retatrutide at 4 mg, 9 mg, or 12 mg weekly, or placebo. After 80 weeks, average weight loss landed at 19.0% on the low dose, 25.9% on the middle dose, and 28.3% on the top dose, compared with just 2.2% on placebo.

That was the highest sponsor-reported mean in a phase 3 obesity readout at the time. It is not a head-to-head finding against semaglutide, tirzepatide, or surgery. The result began as topline company data, and Lilly later presented additional TRIUMPH-1 detail at the June 2026 American Diabetes Association meeting. A complete peer-reviewed paper remains the stronger final record.

The short version: TRIUMPH-1 produced a striking dose-related result, gastrointestinal adverse events and discontinuations also increased with dose, and retatrutide remained investigational as of August 24, 2026.

The numbers, dose by dose

TRIUMPH-1 (registered as NCT05929066) split its 2,339 participants evenly, roughly 1:1:1:1, across the three retatrutide doses and placebo. Everyone started at 2 mg once weekly, and the dose stepped up every four weeks until each person reached their assigned target. The main analysis covers 80 weeks, though a subgroup of participants who started with a BMI of 35 or higher stayed in an extension out to 104 weeks.

Here is the weight loss by arm at 80 weeks: 4 mg produced 19.0% average loss, or about 47.2 pounds. 9 mg produced 25.9%, or about 64.4 pounds. 12 mg produced 28.3%, or about 70.3 pounds. Placebo came in at 2.2%, about 5.5 pounds.

Two extra data points matter more than the average. First, at the 12 mg dose, 45.3% of participants lost 30% or more of their total body weight, a scale of loss historically seen with bariatric surgery rather than an injectable drug. Second, 65.3% of the 12 mg group ended the trial with a BMI under 30, meaning they no longer met the clinical definition of obesity. The extension data adds another wrinkle: the higher-BMI subgroup on 12 mg kept losing weight past week 80, reaching a mean of 30.3% (about 85.0 pounds) by week 104, which suggests the weight loss curve had not leveled off for everyone by the standard trial endpoint.

For context, semaglutide's STEP 1 and tirzepatide's SURMOUNT-1 used different populations, durations, dose designs, and statistical plans. Their headline means are useful landmarks, not proof that retatrutide is superior. Only a direct randomized comparison can answer that question cleanly.

One more detail matters when comparing the dose arms. The percentage is a group mean, not a promise attached to the number on the syringe. It reflects the trial's eligibility rules, escalation design, follow-up, and statistical handling of people who stopped treatment or had missing measurements. Those choices can move the headline result even when the drug itself is unchanged, which is why the full analysis plan matters alongside the average.

What happened beyond the scale

Weight loss is the headline, but modern obesity trials also track the metabolic markers underneath it, and TRIUMPH-1 followed that pattern. In the 12 mg group, Lilly reported a mean waist circumference reduction of about 24.1 cm (9.5 inches), along with improvements in non-HDL cholesterol, triglycerides, systolic blood pressure, and high-sensitivity C-reactive protein. These were reported as secondary endpoints, and the waist reduction lines up with the scale of the overall weight loss.

The glucagon receptor is the part of retatrutide's mechanism that distinguishes it from tirzepatide, which activates GIP and GLP-1 receptors. The broader program has also moved since the first May release: Lilly announced topline TRIUMPH-2 and TRIUMPH-3 results on July 23, 2026. Those additional sponsor reports expand the phase 3 record, but they do not replace complete peer-reviewed publications or the dedicated cardiovascular outcomes trial.

The side effects and who dropped out

The safety profile follows the pattern anyone who has followed GLP-1 drugs will recognize, just turned up a notch. Nausea, diarrhea, constipation, and vomiting were the dominant complaints, they got more common at higher doses, and most cases were described as mild to moderate. At the top 12 mg dose, roughly 42.4% of participants reported nausea, 32.0% diarrhea, 26.1% constipation, and 25.3% vomiting.

One side effect that stands out from this drug class is dysesthesia, an odd tingling or altered skin sensation, which showed up in roughly 5% to 12.5% of retatrutide participants versus under 1% on placebo. It was generally reported as mild, but it is unusual enough to be worth flagging.

The number that tells the real tradeoff story is discontinuation. About 4.1% of people on 4 mg stopped due to side effects, rising to 6.9% on 9 mg and 11.3% on 12 mg, compared with 4.9% on placebo. In plain terms, the dose that delivers the most weight loss is also the dose more people cannot tolerate staying on.

The discontinuation figures are especially useful because they connect efficacy with tolerability. A side effect can be common yet manageable, while a smaller number of participants may find it disruptive enough to stop treatment. Reading both rates prevents two opposite errors: treating every reported symptom as treatment-ending, or discussing the weight-loss mean without acknowledging how many people could not remain on the assigned dose.

Why you still cannot get a prescription for this

As of August 24, 2026, retatrutide remained investigational and was not FDA approved. There was no approved retail retatrutide product. Products sold online under the research label do not carry the identity, purity, and manufacturing assurance of an approved medicine.

TRIUMPH-1 began as a May 21 company topline announcement, with further detail presented at the June 2026 American Diabetes Association meeting. Lilly then announced topline TRIUMPH-2 and TRIUMPH-3 results on July 23. The remaining evidence gap is not a lack of phase 3 activity. It is the absence of complete peer-reviewed reports and regulatory review of the full package.

How to read a headline number like 28.3%

A 28.3% mean sits at the top of a wide distribution. Some trial participants lost far more, some lost much less, and some stopped early because of side effects, which gets absorbed into the statistical analysis rather than showing up as a visible asterisk on the headline. That number also comes from the highest dose, which carries the heaviest side-effect and discontinuation burden, and trial participants receive structured diet and lifestyle coaching that most real-world users will not have access to.

The fair summary is that TRIUMPH-1 reported the largest phase 3 mean in its lane at the time, with a dose-related adverse-event and discontinuation pattern. Cross-trial differences prevent a clean superiority claim, and the product remained investigational as of August 24, 2026.

Educational content only. Not medical advice.

Continue with source-linked research guides